BioRad Laboratories (BIO.B)
(Delayed Data from NYSE)
$279.91 USD
0.00 (0.00%)
Updated Apr 18, 2024 03:59 PM ET
After-Market: $279.65 -0.26 (-0.09%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for BioRad Laboratories, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,671 | 2,802 | 2,923 | 2,546 | 2,312 |
Cost Of Goods | 1,244 | 1,235 | 1,282 | 1,108 | 1,055 |
Gross Profit | 1,427 | 1,567 | 1,641 | 1,438 | 1,257 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,089 | 1,085 | 1,151 | 1,027 | 1,027 |
Income After Depreciation & Amortization | 338 | 483 | 489 | 411 | 230 |
Non-Operating Income | -1,138 | -5,149 | 4,950 | 4,519 | 2,055 |
Interest Expense | 49 | 38 | 2 | 22 | 23 |
Pretax Income | -850 | -4,704 | 5,438 | 4,908 | 2,261 |
Income Taxes | -213 | -1,077 | 1,192 | 1,101 | 502 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -637 | -3,628 | 4,246 | 3,806 | 1,759 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -637 | -3,628 | 4,246 | 3,806 | 1,759 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 338 | 483 | 489 | 411 | 230 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 338 | 483 | 489 | 411 | 230 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 29.21 | 29.79 | 30.21 | 30.16 | 30.18 |
Diluted EPS Before Non-Recurring Items | 11.78 | 14.42 | 15.66 | 10.52 | 7.06 |
Diluted Net EPS (GAAP) | -21.82 | -121.79 | 140.56 | 126.20 | 58.27 |
Fiscal Year end for BioRad Laboratories, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 681.18 | 632.12 | 681.11 | 676.84 |
Cost Of Goods | NA | 314.82 | 296.44 | 318.63 | 314.43 |
Gross Profit | NA | 366.36 | 335.68 | 362.48 | 362.42 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 271.05 | 244.74 | 272.86 | 300.50 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 95.31 | 90.94 | 89.62 | 61.92 |
Non-Operating Income | NA | 345.44 | 58.55 | -1,577.70 | 35.25 |
Interest Expense | NA | 12.36 | 12.40 | 12.34 | 12.34 |
Pretax Income | NA | 428.39 | 137.10 | -1,500.43 | 84.83 |
Income Taxes | NA | 78.68 | 30.85 | -338.18 | 15.87 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 349.71 | 106.26 | -1,162.25 | 68.96 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 349.71 | 106.26 | -1,162.25 | 68.96 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 28.82 | 29.22 | 29.36 | 29.75 |
Diluted EPS Before Non-Recurring Items | NA | 3.10 | 2.33 | 3.00 | 3.34 |
Diluted Net EPS (GAAP) | NA | 11.81 | 3.64 | -39.59 | 2.32 |